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ABSTRACT
Objectives sPiRiT head- to- head (H2H) is a 52- 
week (Wk) trial comparing ixekizumab (iXe) with 
adalimumab (aDa) for simultaneous american College of 
Rheumatology (aCR)50 and Psoriasis area and severity 
index (Pasi)100 responses in 566 patients (distributed 
evenly across both groups) with psoriatic arthritis (Psa). 
iXe was superior to aDa for this primary end point at 
Wk24. We aimed to determine the final efficacy and 
safety results through Wk52 including a prespecified 
subgroup analysis of concomitant conventional synthetic 
disease- modifying anti- rheumatic drugs (csDMaRD) use.
Methods sPiRiT- H2H is a Wk52 multicentre, open- 
label, blinded- assessor study comparing iXe and aDa in 
bionaïve patients with Psa. Patients were randomised 
1:1 to iXe or aDa with stratification by concomitant 
csDMaRD use and presence of moderate- to- severe 
plaque psoriasis. Prespecified end points at Wk24 and 
Wk52 included musculoskeletal, psoriasis, quality- of life 
outcomes, subgroup analyses and safety.
Results a significantly higher proportion of patients 
treated with iXe versus aDa simultaneously achieved 
aCR50 and Pasi100 (39% vs 26%, p<0.001), Pasi100 
(64% vs 41%, p<0.001) at Wk52. efficacy of iXe and 
aDa was similar at Wk52 for aCR50 (49.8% vs 49.8%, 
p=0.924), treat- to- target outcomes, enthesitis and 
dactylitis resolution. Responses to iXe were consistent 
irrespective of concomitant csDMaRD use. significantly 
more patients on iXe monotherapy versus aDa 
monotherapy had simultaneous aCR50 and Pasi100 
(38% vs 19%, p=0.007), and Pasi100 responses (66% 
vs 35%, p<0.001) at Wk52. There were no new safety 
findings for iXe or aDa.
Conclusions iXe provided significantly greater 
simultaneous joint and skin improvement than aDa 
through Wk52 in bionaïve patients with Psa. iXe showed 
better efficacy on psoriasis and performed at least as 
well as aDa on musculoskeletal manifestations. iXe 
efficacy was consistent irrespective of concomitant 
csDMaRD use.
Trial registration number nCT03151551.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic, progressive, 
immune- mediated, inflammatory disease affecting 
the musculoskeletal system, skin and nails.1 Occur-
ring in 0.04%–1% of the population, the disease 
Key messages
What is already known about this subject?
 ► Prior to disclosure of the primary results of 
SPIRIT head- to- head (H2H) trial comparing 
efficacy and safety of ixekizumab with 
adalimumab in bionaïve patients, direct 
comparative data were lacking in psoriatic 
arthritis (PsA).
 ► Ixekizumab was shown to be superior to 
adalimumab for simultaneous achievement of 
American College of Rheumatology (ACR)50 
and Psoriasis Area and Severity Index (PASI)100 
responses along with non- inferiority for ACR50 
and superiority for PASI100 achievement at 
week 24.
What does this study add?
 ► This work presents final SPIRIT- H2H data 
through 52 weeks: significantly higher 
simultaneous ACR50 and PASI100 responses as 
well as PASI75/90/100 responses on ixekizumab 
than adalimumab were maintained.
 ► At week 52, treatment with ixekizumab was 
at least as efficacious as adalimumab based 
on the ACR20/50/70 responses, PsA- specific 
composite disease activity measures, enthesitis 
and dactylitis as well as physical function 
outcomes, with faster effects seen until week 24 
for most outcomes.
 ► Ixekizumab efficacy was consistent throughout 
52 weeks either as monotherapy or in 
combination with csDMARDs.
 ► There were no new safety findings for either 
ixekizumab or adalimumab.
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bDMARD-naïve adults with active PsA
N=684
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Other, n=3
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Adalimumab, n=283 Ixekizumab, n=283
Completed week 52, 
n=237
Completed week 52, 
n=246
Discontinued, n=46
Adverse event, n=21
Protocol deviation, n=2
Withdrawal by subject, n=14
Lack of efficacy, n=8
Lost to follow-up, n=1
Discontinued, n=37
Adverse event, n=13
Protocol deviation, n=2
Withdrawal by subject, n=9
Lack of efficacy, n=9
Lost to follow-up, n=1
Physician decision, n=2
Other, n=1
Figure 1 Participant flow diagram through week 52. bDMARD, biological disease- modifying antirheumatic drug; PsA, psoriatic arthritis.
Key messages
How might this impact on clinical practice or future 
developments?
 ► SPIRIT- H2H study comparing ixekizumab versus adalimumab 
is the first fully disclosed direct head- to- head study in PsA; 
its findings over 52 weeks will inform future treatment 
recommendations and may impact selection of therapy in 
bionaïve patients with active PsA.
may result in deformities, impaired physical function, decreased 
quality of life and increased mortality.2 3 Initial treatment 
traditionally involves non- steroidal anti- inflammatory drugs, 
glucocorticoids and conventional synthetic disease- modifying 
anti- rheumatic drugs (csDMARDs).4–6 When csDMARDs are 
ineffective, biological (b)- DMARDs such as tumour necrosis 
factor (TNF)- inhibitors, anti- interleukin (IL)-12/23, anti- IL- 17A 
inhibitors or targeted synthetic DMARD are recommended, 
with TNF- inhibitors being frequently the first- line bDMARD 
therapy.3 7–10 bDMARDs can be used as monotherapy or in 
combination with csDMARDs, most commonly methotrexate 
(MTX). Ixekizumab (IXE) is an immunoglobulin G4 mono-
clonal antibody that selectively inhibits IL- 17A and its efficacy 
across multiple PsA domains was previously established.11 12 
Despite the approval of numerous bDMARDs for the treatment 
of PsA, no direct comparisons are available to enable evidence- 
based treatment decisions.
SPIRIT head- to- head (H2H) is a 52- week (Wk) trial evalu-
ating efficacy and safety of IXE and ADA, a TNF- inhibitor, in 
patients with active PsA naïve to bDMARDs. We reported previ-
ously the results of the primary and key secondary end points 
at Wk24, which were all met, demonstrating superiority of 
IXE versus ADA for the simultaneous achievement of Amer-
ican College of Rheumatology (ACR)50 and Psoriasis Area and 
Severity Index (PASI)100 responses, along with superiority for 
PASI100 responses and non- inferiority for ACR50 responses.13
Here, we report the efficacy and safety results of SPIRIT- H2H 
study through Wk52, including results of the prespecified 
subgroup analyses based on concomitant csDMARD use and 
presence or absence of moderate- to- severe psoriasis.
MeTHOdS
Participants
Participants had to be ≥18 years of age, with a confirmed diag-
nosis of PsA for ≥6 months and fulfilling the Classification for 
Psoriatic Arthritis (CASPAR) criteria. Other major inclusion 
criteria were: previous inadequate response to ≥1 csDMARD, 
no prior exposure to bDMARDs, ≥3/68 tender joints, ≥3/66 
swollen joints, and psoriatic skin lesions affecting a body surface 
area (BSA) of ≥3%.
Study design
SPIRIT- H2H is a Wk52, phase IIIb/IV, multicentre, randomised, 
open- label, parallel- group, assessor- blinded study evaluating 
the efficacy and safety of IXE versus ADA. The detailed study 
design was published previously.13 Randomisation was stratified 
by concomitant csDMARD use and presence of moderate- to- 
severe plaque psoriasis (defined as PASI ≥12 combined with a 
static Physician Global Assessment ≥3 (of 5) and BSA ≥10%) 
at baseline (yes/no). Participants received approved label dosing 
of the assigned treatment based on the presence or absence of 
moderate- to- severe psoriasis as described in online supplemen-
tary information.13 Permitted csDMARDs were MTX (oral or 
parenteral, 10–25 mg/week), leflunomide (up to 20 mg/day), 
sulfasalazine (up to 3 g/day) or ciclosporin (up to 5 mg/kg/day) 
initiated at least 12 weeks prior to baseline and at stable doses 
as described.13 No change in csDMARD dose was allowed 
during the first 24 weeks of the study. Study visits took place at 
screening, baseline (week 0) and postbaseline at weeks 4, 8, 12, 
16, 24, 32, 40 and 52.
efficacy end points
The primary end point was superiority of IXE to ADA as 
measured by the proportion of patients who simultaneously 
achieved ACR50 and PASI100 responses at Wk24. Non- 
inferiority of IXE compared with ADA for ACR50 response and 
superiority for PASI100 response at Wk24 were key secondary 
end points. An ACR50 response was defined as an improve-
ment by ≥50% from baseline in the tender joint count, swollen 
joint count and ≥3 of the following five measurements: Health 
Assessment Questionnaire- Disability Index (HAQ- DI), C reac-
tive protein, patient’s assessment of pain Visual Analogue Scale 
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Table 1 Baseline demographics and disease characteristics
IXe (n=283) AdA (n=283)
Baseline demographics
Age, years 47.5 (12.0) 48.3 (12.3)
Sex, n (%)
  Male 162 (57) 150 (53)
Race, n (%)
  White 222 (78) 211 (75)
  Asian 29 (10) 33 (12)
Body mass index, kg/m2 30.0 (6.9) 29.7 (8.3)
Duration of symptoms since PsA diagnosis, years 6.6 (7.4) 5.9 (6.4)
Duration of symptoms since psoriasis diagnosis, 
years
16.1 (13.1) 14.7 (12.6)
Concomitant csDMARD use, n (%) 193 (68) 199 (70)
  Methotrexate use, n (%) 167 (59) 169 (60)
  Leflunomide use, n (%) 17 (6.0) 21 (7.4)
  Sulfasalazine use, n (%) 21 (7.4) 12 (4.2)
  Ciclosporin use, n (%) 5 (1.8) 10 (3.5)
Baseline disease scores
Tender joint count (0–68) 19.1 (12.7) 21.3 (15.4)
Swollen joint count (0–66) 10.1 (7.5) 10.7 (8.1)
Patient pain VAS, mm 59.7 (21.9) 62.4 (21.1)
Patient’s global assessment of disease activity 
VAS, mm
62.4 (20.3) 65.2 (20.7)
Physician’s global assessment of disease activity 
VAS, mm
58.9 (17.5) 59.4 (18.2)
HAQ- DI (0–3) 1.2 (0.6) 1.3 (0.7)
C reactive protein, mg/L 9.8 (13.7) 10.5 (19.3)
SPARCC Enthesitis Index >0, n (%) 189 (67) 171 (60)
SPARCC Enthesitis Index* 4.9 (3.5) 5.7 (3.8)
LEI >0, n (%) 159 (56) 147 (52)
LEI† 2.5 (1.4) 2.7 (1.5)
LDI- B >0, n (%) 42 (15) 58 (21)
LDI- B‡ 40.1 (42.4) 55.8 (128.4)
Moderate- to- severe psoriasis, n (%) 49 (17) 51 (18)
PASI ≥12, n (%) 55 (19) 57 (20)
sPGA ≥3, n (%) 173 (61) 181 (64)
BSA ≥3%, n (%) 283 (100) 283 (100)
BSA ≥10%, n (%) 113 (40) 104 (37)
PASI 7.9 (8.7) 7.7 (7.3)
Percentage BSA 14.8 (18.4) 12.9 (15.6)
DLQI 9.8 (7.6) 9.8 (7.6)
NAPSI fingernails >0, n (%) 191 (68) 177 (63)
NAPSI fingernails§ 19.7 (18.5) 19.1 (16.3)
Unless indicated otherwise, data are presented as mean (SD).
*Assessed in patients with SPARCC Enthesitis Index >0 at baseline.
†Assessed in patients with LEI >0 at baseline.
‡Assessed in patients with LDI- B >0 at baseline.
§Assessed in patients with NAPSI >0 at baseline.
ADA, adalimumab; BSA, body surface area; csDMARD, conventional synthetic disease- 
modifying antirheumatic drug; DLQI, Dermatology Life Quality Index; HAQ- DI, Health 
Assessment Questionnaire- Disability Index; IXE, ixekizumab; LDI- B, Leeds Dactylitis 
Index- Basic; LEI, Leeds Enthesitis Index; NAPSI, Nail Psoriasis Area and Severity Index; 
PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SPARCC, Spondyloarthritis 
Research Consortium of Canada; sPGA, static physician’s global assessment; VAS, Visual 
Analogue Scale.
(VAS, 100 mm), patient’s global assessment of disease activity 
VAS and physician’s global assessment of disease activity VAS. 
A PASI100 was defined as 100% improvement from baseline 
PASI score. Nine patients with active psoriasis and BSA ≥3% 
were assessed as PASI=0 at baseline, a medical inconsistency 
that was resolved using medical judgement and were considered 
PASI100 responders if PASI=0 and BSA=0 at postbaseline visits. 
Multiple analyses to assess the robustness of this approach were 
conducted.
Prespecified outcomes at Wk52 included the proportion 
of patients achieving simultaneous ACR50 and PASI100 
responses; ACR20/50/70 responses; Minimal Disease Activity 
(MDA); modified Composite Psoriatic Disease Activity Index 
(mCPDAI) change from baseline; resolution of enthesitis, 
as measured by the Spondyloarthritis Research Consortium 
of Canada Enthesitis Index (SPARCC Enthesitis Index=0) 
and Leeds Enthesitis Index (LEI=0) among patients with 
enthesitis at baseline (SPARCC Enthesitis Index >0 or LEI 
>0 at baseline); resolution of dactylitis, as measured by the 
Leeds Dactylitis Index- Basic (LDI- B=0) among patients with 
dactylitis at baseline (LDI- B >0); PASI 75/90/100 responses, 
resolution of fingernail psoriasis (Nail Psoriasis Area and 
Severity Index (NAPSI) score=0) and change from baseline 
in NAPSI score; quality- of- life measures, namely Dermatology 
Life Quality Index score of 0 or 1 (DLQI (0, 1)), achieve-
ment of minimal clinically important difference (MCID) of 
≥0.35- point improvement from baseline in HAQ- DI (among 
patients with ≥0.35 at baseline) and Short Form-36 Physical 
Component Summary (SF-36 PCS). Post hoc analyses included 
outcomes based on Disease Activity in PSoriatic Arthritis 
(DAPSA) and Very Low Disease Activity (VLDA) scores.
Safety
Treatment- emergent adverse events (TEAEs) were defined as 
an event that first occurred or worsened in severity after the 
first dose of study treatment and on or prior to the date of 
the last visit within the treatment time. Adverse events (AEs) 
of special interest included cytopenias, infections, injec-
tion site reactions, allergic reactions, cerebrocardiovascular 
events, malignancies, depression, inflammatory bowel disease 
(IBD) and interstitial lung disease. Cardiovascular events and 
suspected IBD were adjudicated by external clinical events 
committees.
Statistical analysis
Efficacy
Analyses of efficacy end points were performed at the Wk52 
database lock for the intent- to- treat population consisting of all 
randomised patients according to the treatment to which they 
were assigned at Wk0.
Categorical variables were assessed using logistic regression 
models with treatment, concomitant csDMARD use at base-
line and presence of moderate- to- severe plaque psoriasis at 
baseline as factors. Patients were considered non- responders if 
they did not meet the clinical response criteria or had missing 
clinical response data at a particular time point of analysis. 
Continuous efficacy and health outcome variables were anal-
ysed using mixed effects model of repeated measures analysis. 
The models included treatment group, concomitant csDMARD 
use at baseline, presence of moderate- to- severe plaque 
psoriasis at baseline, visit- as- fixed factors, baseline value as 
covariate and baseline- by- visit and treatment- by- visit interac-
tion terms. In addition, logistic regression models were used 
to test treatment- by- subgroup interaction, where treatment, 
subgroup and the interaction of treatment- by- subgroup were 
included as factors. The treatment- by- subgroup interaction 
was tested at the significance level of 0.10. Treatment group 
effects were evaluated within each category of the subgroup 
using Fisher’s exact test, regardless of whether the interaction 
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Table 2 Efficacy and health outcomes at Wk52
IXe (n=283) AdA (n=283)
Treatment difference IXe 
vs AdA (95% CI)
IXe vs AdA p 
value
ACR50+PASI100 n (%) 111 (39.2) (33.5 to 44.9) 74 (26.1) (21.0 to 31.3) 13.1 (5.4 to 20.7) <0.001
ACR50 141 (49.8) (44.0 to 55.6) 141 (49.8) (44.0 to 55.6) 0.0 (–8.2 to 8.2) 0.924
PASI100 182 (64.3) (58.7 to 69.9) 117 (41.3) (35.6 to 47.1) 23.0 (15.0 to 31.0) <0.001
PsA end points
  ACR20 197 (69.6) (64.3 to 75.0) 195 (68.9) (63.5 to 74.3) 0.7 (–6.9 to 8.3) 0.791
  ACR70 100 (35.3) (29.8 to 40.9) 97 (34.3) (28.7 to 39.8) 1.1 (–6.8 to 8.9) 0.733
  MDA 134 (47.3) (41.5 to 53.2) 116 (41.0) (35.3 to 46.7) 6.4 (–1.8 to 14.5) 0.108
  VLDA* 66 (23.3) (18.4 to 28.2) 54 (19.1) (14.5 to 23.7) 4.2 (–2.5 to 11.0) 0.189
  DAPSA remission (≤4)* 85 (30.0) (24.7 to 35.4) 80 (28.3) (23.0 to 33.5) 1.8 (–5.7 to 9.3) 0.579
  DAPSA low disease activity or remission (≤14)* 174 (61.5) (55.8 to 67.2) 166 (58.7) (52.9 to 64.4) 2.8 (–5.2 to 10.9) 0.428
  DAPSA, LSM change from baseline (SE) −33.8 (0.9) −32.4 (0.9) −1.4 (–3.7 to 0.9) 0.219
  mCPDAI, LSM change from baseline (SE) −4.4 (0.1) −3.9 (0.1) −0.5 (–0.8 to –0.2) 0.004
  SPARCC Enthesitis Index=0† 107 (56.6) (49.5 to 63.7) 83 (48.5) (41.0 to 56.0) 8.1 (–2.2 to 18.4) 0.097
  LEI=0‡ 98 (61.6) (54.1 to 69.2) 84 (57.1) (49.1 to 65.1) 4.5 (–6.5 to 15.5) 0.392
  LDI- B=0§ 35 (83.3) (72.1 to 94.6) 47 (81.0) (70.9 to 91.1) 2.3 (–12.8 to 17.4) 0.620
  PASI75 222 (78.4) (73.7 to 83.2) 194 (68.6) (63.1 to 74.0) 9.9 (2.7 to 17.1) 0.008
  PASI90 206 (72.8) (67.6 to 78.0) 153 (54.1) (48.3 to 59.9) 18.7 (10.9 to 26.5) <0.001
  NAPSI fingernails=0¶ 129 (67.5) (60.9 to 74.2) 104 (58.8) (51.5 to 66.0) 8.8 (–1.1 to 18.6) 0.060
  NAPSI, LSM change from baseline (SE) 169 (0.7) 154 (0.7) −2.7 (–4.6 to –0.8) 0.005
Quality- of- life end points
  HAQ- DI improvement by ≥0.35** 168 (66.7) (60.8 to 72.5) 164 (64.6) (58.7 to 70.4) 2.1 (–6.2 to 10.4) 0.605
  DLQI (0–1) 167 (59.0) (53.3 to 64.7) 138 (48.8) (42.9 to 54.6) 10.2 (2.1 to 18.4) 0.014
  SF-36 PCS change from baseline 10.1 (0.5) 9.6 (0.5) 0.5 (0.7) 0.439
Unless otherwise indicated, values are presented as n (%), 95% CI.
*Post hoc analysis.
†Assessed for patients with SPARCC Enthisitis Index score >0 at baseline.
‡Assessed for patients with LEI score >0 at baseline.
§Assessed for patients with LDI- B score >0 at baseline.
¶Assessed for patients with NAPSI fingernails score >0 at baseline.
**Assessed for patients with HAQ- DI score ≥0.35 at baseline.
ACR, American College of Rheumatology; ADA, adalimumab; DAPSA, Disease Activity in Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; HAQ- DI, Health Assessment 
Questionnaire- Disability Index; IXE, ixekizumab; LDI- B, Leeds Dactylitis Index- Basic; LEI, Leeds Enthesitis Index; LSM, least squares mean; mCPDAI, modified Composite Psoriatic 
Disease Activity Index; MDA, Minimal Disease Activity; NAPSI, Nail Psoriasis Area and Severity Index; NRI, non- responder imputation; PASI, Psoriasis Area and Severity Index; PCS, 
Physical Component Summary; PsA, psoriatic arthritis; SF-36, Medical Outcomes Study 36- Item Short Form Health Survey; SPARCC, Spondyloarthritis Research Consortium of 
Canada; VLDA, Very Low Disease Activity.
was statistically significant. No multiplicity adjustments were 
conducted for the Wk52 analysis.
Safety
Descriptive statistics were performed on the safety population, 
defined as all randomised patients who received ≥1 dose of the 
study treatment.
ReSulTS
Participants
From the 684 screened patients, 566 were randomised equally 
between IXE and ADA treatments. Overall, 246 (87%) patients 
treated with IXE and 237 (84%) treated with ADA completed 
the Wk52 study visit. Concomitant csDMARD use was stable 
in the majority of the patients over 52 weeks except for three 
patients stopping MTX treatment after W24 (two ADA, one 
IXE) and seven patients changing MTX dose after W24 (three 
ADA, four IXE). Fewer patients treated with IXE than ADA 
discontinued for AEs, 13 vs 21, respectively (figure 1). Baseline 
demographics and disease characteristics were balanced between 
IXE and ADA groups (table 1).
efficacy
The Wk52 efficacy results are summarised in table 2. A signifi-
cantly higher proportion of patients treated with IXE achieved 
simultaneous ACR50 and PASI100 versus ADA (39.2% vs 
26.1%; p<0.001). Significant differences were observed as early 
as Wk8 and maintained throughout the study (figure 2A). IXE 
and ADA treatment resulted in similar response rates for ACR50 
(49.8% vs 49.8%) (figure 2B), ACR20 (69.6% vs 68.9%) and 
ACR70 (35.3% vs 34.3%) at Wk52 (figure 3A,B).
The proportion of patients achieving MDA, VLDA, DAPSA 
remission and DAPSA low disease activity or remission was not 
significantly different between IXE and ADA at Wk52. However, 
faster onset of response to IXE than ADA with significant 
differences at Wk24 was observed for MDA (47.7% vs 35.3%; 
p=0.003) (online supplementary figure 1A), VLDA (17.3% 
vs 10.2%; p=0.015) and DAPSA remission (26.5% vs 18.0%; 
p=0.016) (online supplementary figure 1B). Patients treated 
with IXE achieved significantly greater improvements from 
baseline in mCPDAI compared with ADA (online supplementary 
figure 1C) at Wk52 (−4.35 vs −3.85; p=0.004), with signifi-
cant differences observed at the first postbaseline assessment at 
Wk12 through Wk52. Comparable efficacy of IXE versus ADA 
at Wk52 was shown for enthesitis resolution as measured by 
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Figure 2 Key clinical response rates through week 52 (non- responder 
imputation). (A) Percentage of patients achieving simultaneous 
American College of Rheumatology (ACR)50 and Psoriasis Area and 
Severity Index (PASI)100 response. (B) Percentage of patients achieving 
ACR50 response. (C) Percentage of patients achieving PASI100 response. 
Ixekizumab (IXE) vs adalimumab (ADA): *p<0.05, †p<0.01, ‡p<0.001.
SPARCC (56.6% vs 48.5%), LEI (61.6% vs 57.1%) and dactylitis 
resolution LDI- B (83.3% vs 81.0%), as well as improvement in 
physical function by achieving MCID in HAQ- DI (66.7% vs 
64.6%), respectively (table 2).
IXE treatment resulted in significantly higher response rates 
versus ADA at Wk52 for PASI75 (78.4% vs 68.6%; p=0.008) 
(figure 3C), PASI90 (72.8% vs 54.1%; p≤0.001) (figure 3D) and 
PASI100 (64.3% vs 41.3%; p≤0.001), beginning as early as Wk4 
and persisting through to end of the trial (p≤0.001) (figures 2C 
and 3C,D). At Wk52, a similar rate of nail psoriasis resolution 
was observed. However, IXE- treated subjects achieved signifi-
cantly greater improvement in NAPSI scores from baseline 
versus ADA (−17.78 vs −15.08; p=0.005, online supplemen-
tary figure 1D). Rapid and significantly greater improvements in 
skin- related quality of life were also observed on IXE (DLQI (0, 
1)) as early as Wk4 through Wk52 (online supplementary figure 
1E, table 2).
Subgroup analysis
At Wk52, no differential treatment was observed when used in 
monotherapy or combination with csDMARD on simultaneous 
ACR50 and PASI100, ACR50 or PASI100 response rates (inter-
action p values of 0.269, 0.139 and 0.200, respectively). IXE as 
monotherapy or in combination with csDMARD showed similar 
response, while ADA response was influenced by csDMARD use. 
Simultaneous ACR50 and PASI100 achievement: monotherapy, 
IXE 37.8%, ADA 19.0%, p=0.007; combination therapy, IXE 
39.9%, ADA 29.1%, p=0.026. ACR50: monotherapy, IXE 
51.1%, ADA 41.7%, p=0.227; combination therapy, IXE 
49.2%, ADA 53.3%, p=0.479. PASI100: monotherapy, IXE 
65.6%, ADA 34.5%, p≤0.001; combination therapy, IXE 
63.7%, ADA 44.2%, p≤0.001 (figure 4).
Similar observations were made when looking at the differ-
ence between IXE and ADA across severity of psoriasis at base-
line, where the different dosing of IXE and ADA administered 
in patients with PsA with/without moderate- to- severe psoriasis 
did not influence IXE efficacy as measured by simultaneous 
ACR50 and PASI100 response rate (interaction p=0.277): 
with moderate- to- severe psoriasis, IXE 38.8%, ADA 17.6%, 
p=0.026; without moderate- to- severe psoriasis, IXE 39.3%, 
ADA 28.1%, p=0.014. ACR50 (interaction p=0.378): with 
moderate- to- severe psoriasis, IXE 55.1%, ADA 62.7%, 
p=0.542; without moderate- to- severe psoriasis, IXE 48.7%, 
ADA: 46.8%, p=0.711. PASI100 (interaction p=0.199): 
with moderate- to- severe psoriasis, IXE 59.2%, ADA 25.5%, 
p≤0.001; without moderate- to- severe psoriasis, IXE 65.4%, 
ADA 45.0%, p≤0.001; at Wk52 (figure 5).
Safety
There were numerically more TEAEs in the IXE- treated popu-
lation compared with ADA (73.9% vs 68.6%, p=0.194) mostly 
classified as mild or moderate (table 3). There were fewer severe 
TEAEs occurring in the IXE- treated patients versus ADA (3.2% 
vs 7.1%), serious AEs (4.2% vs 12.4%) and discontinuations 
due to AEs (4.2% vs 7.4%). No deaths occurred during the 
study. Serious infections were numerically lower in IXE treat-
ment compared with ADA (1.8% vs 2.8%), while the number of 
Candida infections was higher in the IXE- treated group (2.5% 
vs 1.1%). There was one case each of legionella pneumonia and 
lymph node tuberculosis reported in the ADA- treated group.
Injection site reactions were more frequent in the IXE- treated 
group versus ADA (10.6% vs 3.5%) while the number of discon-
tinuations due to injections site reaction was lower in IXE versus 
ADA (0.7% vs 1.1%). The number of hypersensitivity reac-
tions and cerebrocardiovascular events were similar across both 
groups. Four cases of malignancy were reported in the ADA- 
treated population (2 basal cell carcinoma, rectal carcinoma and 
gastrointestinal stromal tumour). No malignancies occurred in 
the IXE- treated group. One patient discontinued due to rectal 
carcinoma in the ADA- treated group. Fewer events of cytopenia 
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Figure 3 Additional efficacy outcomes—American College of Rheumatology (ACR) and Psoriasis Area and Severity Index (PASI). Percentage of 
patients achieving (A) ACR20, (B) ACR70, (C) PASI75 and (D) PASI90, through 52 weeks. Ixekizumab (IXE) vs adalimumab (ADA): †p<0.01, ‡p<0.001.
were observed in the IXE versus ADA- treated group (3.2% vs 
4.2%).
Two cases of IBD reported in the IXE- treated group during 
the period of Wks0–24 were adjudicated. One case of Crohn’s 
met the EPIdémiologie des Maladies de l’Appareil Digestif 
(EPIMAD) criteria of confirmed IBD and one case of ulcerative 
colitis did not meet EPIMAD criteria of confirmed IBD as it was 
adjudicated as possible.13 No new case was reported during Wks 
24–52 period.
dISCuSSIOn
Although several bDMARDs with different mechanisms of action 
are approved for use in PsA, true head- to- head trials against an 
active agent and not versus placebo are still lacking. ADA has 
previously been included as an active reference arm in SPIRIT- P1 
(NCT01695239; IXE vs placebo) and OPAL (NCT01877668; 
tofacitinib vs placebo) studies; however, these trials were not 
statistically powered for direct comparisons.11 14 SPIRIT- H2H is 
the first completed PsA trial directly comparing two bDMARDs, 
IXE and ADA, in patients with active PsA and an inadequate 
response to csDMARD/s. This study met the primary end point 
at Wk24 by demonstrating the superiority of IXE over ADA for 
the simultaneous achievement of ACR50 and PASI100. The key 
secondary end points of non- inferiority of IXE for ACR50 and 
superiority for PASI100 at Wk24 were also met.13 The present 
work reports the Wk52 results of SPIRIT- H2H, including results 
of the prespecified subgroup analyses with respect to the concom-
itant csDMARD use or presence/absence of moderate- to- severe 
psoriasis. Significantly higher proportions of patients treated 
with IXE versus ADA simultaneously achieving ACR50 and 
PASI100 responses were sustained through Wk52. Importantly, 
response rates for IXE were consistent irrespective of concomi-
tant csDMARD use, while numerically higher response rates for 
ADA were seen when used in combination with csDMARDs than 
in monotherapy.
Similar to SPIRIT- H2H, a study comparing secukinumab versus 
ADA (NCT02745080, EXCEED 1) has enrolled bDMARD- naïve 
patients with inadequate response to csDMARDs. However, key 
differences between the two studies include primary outcome 
(ACR20 in EXCEED vs ACR50+PASI100 in SPIRIT- H2H), 
blinding (double- blind in EXCEED 1 vs open- label design 
with blinded assessments in SPIRIT- H2H) and concomitant 
csDMARD use, which was not allowed in EXCEED 1. The 
results of EXCEED 1 were only presented in an abstract form 
thus far.15
Due to disease heterogeneity in PsA, the requirement of 
assessing multiple PsA domains to identify appropriate treat-
ments for individual patients is important. Therefore, we used 
simultaneous achievement of a relatively rigorous end point for 
articular disease (ACR50) and a very stringent end point for the 
skin disease (PASI100) at Wk24 as the primary end point for this 
study. IXE treatment demonstrated significantly higher rates for 
the simultaneous achievement of ACR50 and PASI100 as early 
as Wk8 and throughout Wk52, highlighting the maintenance of 
comprehensive disease control throughout the study. A signifi-
cantly higher PASI100 response rate and change from baseline 
in NAPSI score was shown in the IXE group as early as the 
first postbaseline assessment (Wk4 for PASI100 and Wk12 for 
NAPSI) and through Wk52. IXE and ADA treatment resulted in 
similar responses in other PsA domains at Wk52: ACR20/50/70; 
MDA, VLDA, DAPSA remission; enthesitis and dactylitis reso-
lution. At Wk24, significantly higher proportions of patients 
on IXE achieved resolution of enthesitis (by SPARCC), MDA, 
VLDA and DAPSA remission, indicating a faster onset of action 
of IXE versus ADA on the musculoskeletal symptoms of PsA, 
not only on psoriasis as evidenced by PASI responses and NAPSI 
resolution. Significantly larger improvement from baseline in 
mCPDAI was observed in the IXE treatment group compared 
with ADA, starting at the first postbaseline assessment at Wk12 
and persisting to Wk52.
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Figure 4 Subgroup analysis based on conventional synthetic disease- modifying anti- rheumatic drug (csDMARD) use—clinical response rates for 
the key outcomes. Percentage of patients achieving simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index 
(PASI)100 responses (A) without concomitant csDMARD use and (B) with concomitant csDMARD use (treatment- by- subgroup interaction p=0.269). 
Percentage of patients achieving ACR50 (C) without concomitant csDMARD use and D) with concomitant csDMARD use (treatment- by- subgroup 
interaction p=0.139). Percentage of patients achieving PASI100 (E) without concomitant csDMARD use and (F) with concomitant csDMARD use 
(treatment- by- subgroup interaction p=0.200). Ixekizumab (IXE) vs adalimumab (ADA): *p<0.05, †p<0.01, ‡p<0.001.
The beneficial effect of the concomitant use of csDMARDs 
in patients with PsA treated with bDMARDs is still debated. 
Therefore, concomitant use of csDMARDs was allowed during 
the study, with the requirement for stable doses 8 weeks prior 
to baseline and until Wk24 (primary end point). Randomisation 
was also stratified according to concomitant csDMARD use to 
enable exploring the response- modifying effect of csDMARD on 
IXE and ADA treatment. Interestingly, concomitant csDMARD 
use had a response- modifying effect in the ADA group, but not 
in the IXE group. This was manifested by numerically higher 
proportions of patients achieving simultaneous ACR50 and 
PASI100 as well as PASI100 responses on ADA with concom-
itant csDMARD use compared with monotherapy in contrast 
to consistent response rates in the IXE group irrespective of 
concomitant csDMARD use; these observations can inform 
decision making when considering concomitant csDMARD to 
IXE or ADA. Interestingly, the differences in the dosing regimen 
of IXE and ADA with respect to the presence or absence of 
moderate- to- severe psoriasis had no effect on the response to 
either IXE or ADA.
Overall, the safety profiles of both drugs were consistent 
with previous clinical trials and the regulatory labels. However, 
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Figure 5 Subgroup analysis based on presence/absence of moderate- to- severe psoriasis—clinical response rates for the key outcomes. Percentage 
of patients achieving simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 (A) with moderate- 
to- severe psoriasis and (B) without moderate- to- severe psoriasis (treatment- by- subgroup interaction p=0.277). (C) Percentage of patients with 
moderate- to- severe psoriasis achieving ACR50 and (D) patients without moderate- to- severe psoriasis achieving ACR50 (treatment- by- subgroup 
interaction p=0.378). (E) Percentage of patients with moderate- to- severe psoriasis achieving PASI100 and (F) patients without moderate- to- severe 
psoriasis achieving PASI100 (treatment- by- subgroup interaction p=0.199). Ixekizumab (IXE) vs adalimumab (ADA): *p<0.05, †p<0.01, ‡p<0.001.
a number of numerical differences between the treatment 
groups were identified. Although IXE treatment resulted in 
more TEAEs, the majority of these were classified as mild and 
moderate in severity, while more severe TEAEs and serious AEs 
were observed in the ADA group. The number of serious infec-
tions and proportion of patients who discontinued the study 
due to AEs was also numerically higher with ADA treatment. 
The injection site reactions were higher in the IXE group, while 
the number of patients who discontinued due to in injection site 
reaction was similar. One case of Crohn’s disease was adjudi-
cated and confirmed in the IXE- treated group.
The limitations of the study include the open- label design, 
which may have contributed to outcome assessment bias, 
although efforts were made to minimise this by using blinded 
assessors for key outcomes. On the other hand, open- label 
design better represents real- world clinical setting where patients 
are aware of the treatment assignment. Antidrug antibodies to 
IXE or ADA were not measured, which would have provided 
insight into the immunogenicity and possible explanation for the 
differing impact of concomitant csDMARDs.
In summary, IXE treatment resulted in significantly greater 
simultaneous ACR50 and PASI100 responses versus ADA through 
1 year of the study. IXE performed as well as ADA across muscu-
loskeletal PsA domains with a faster onset of action and showed 
significantly greater efficacy on the skin and nails through Wk52. 
Concomitant csDMARD use had a response- modifying effect in 
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Table 3 Safety outcomes
IXe (n=283) AdA (n=283)
Treatment- emergent adverse events 209 (73.9) 194 (68.6)
  Mild 95 (33.6) 85 (30.0)
  Moderate 105 (37.1) 89 (31.4)
  Severe 9 (3.2) 20 (7.1)
Serious adverse events 12 (4.2) 35 (12.4)
Deaths 0 0
Discontinuations due to adverse events 12 (4.2) 21 (7.4)
Adverse events of special interest
  Infections 119 (42) 111 (39.2)
   Serious infections 5 (1.8) 8 (2.8)
   Candida infections 7 (2.5) 3 (1.1)
  Injection site reactions 30 (10.6) 10 (3.5)
  Allergic/Hypersensitivity reactions 11 (3.9) 13 (4.6)
  Cerebrocardiovascular events* 5 (1.8) 7 (2.5)
  Malignancies 0 4 (1.4)
  Depression 5 (1.8) 9 (3.2)
  IBD† 2 (0.7) 0
   Ulcerative colitis†‡ 1 (0.4) 0
   Crohn’s disease†‡ 1 (0.4) 0
  Cytopenias 9 (3.2) 12 (4.2)
Values presented as n (%).
*Cerebrocardiovascular events are defined using terms from the following 
subcategories: cardiovascular death, MI, hospitalisation for unstable angina, 
hospitalisation for heart failure, hospitalisation for serious arrhythmia, 
hospitalisation for hypertension, resuscitated sudden, death, cardiogenic shock 
due to MI, coronary revascularisation procedure, neurologic stroke and peripheral 
vascular events.
†EPIMAD criteria for adjudication of suspected IBD define ‘probable’ and ‘definite’ 
classifications as confirmed cases. Only one case met the EPIMAD criteria of 
confirmed IBD.13
‡The event was reported as colitis ulcerative and was adjudicated as possible 
ulcerative colitis, which did not meet the EPIMAD criteria as confirmed IBD.
§Event was reported as colitis and was adjudicated as probable Crohn’s disease 
and met the EPIMAD criteria as confirmed IBD.
ADA, adalimumab; EPIMAD, EPIdémiologie des Maladies de l’Appareil Digestif; IBD, 
inflammatory bowel disease; IXE, ixekizumab; MI, myocardial infarction.
the ADA group, but not the IXE group; responses to IXE were 
consistent in monotherapy and combination with csDMARDs. 
The results of this study are informative for the management of 
patients with PsA in routine clinical practice.
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